Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Novartis (NVS) Stock Undervalued Right Now?

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear from the end of patent protection on some drugs.

Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper

On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion.

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Since my previous article in May, shares of Novartis AG have gone on to outperform the S&P 500 index. The drugmaker's revenue and core EPS topped analysts' expectations in Q3. Novartis' debt load remains very manageable.

Novartis: It's Not Too Late To Buy This Dividend Stock Now

Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth but investor disappointment stemmed from a revenue adjustment affecting Pluvicto. Novartis raised its full-year guidance, projecting double-digit sales growth for the remainder of 2024.

Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs.

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Novartis AG (NYSE:NVS ) Q3 2024 Earnings Conference Call October 29, 2024 9:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Richard Vosser - J.P. Morgan Emily Field - Barclays Capital Florent Cespedes - Bernstein Simon Baker - Redburn Atlantic Graham Parry - Bank of America Matthew Weston - UBS James Quigley - Goldman Sachs Peter Welford - Jefferies Etzer Darout - BMO Capital Markets Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Securities Rajesh Kumar - HSBC Steve Scala - TD Cowen Emmanuel Papadakis - Deutsche Bank Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 Results Release Conference Call and Live Webcast.

Novartis AG (NVS) Q3 2024 Earnings Call Transcript

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its outlook for 2024.

Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook

While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Novartis (NVS) on Tuesday posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali.

Novartis Posts Results Above Estimates, Raises Outlook

Novartis stock was set to slip further from technical support Tuesday, despite a solid Q3 performance and an upgraded outlook.

Novartis Earnings Show Q3 Momentum, But Shares Lose Support

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped analysts' expectations, boosted by revenue from its key drugs.

Novartis Lifts Guidance Again After Key Drugs Help Results

Check Point Software Technologies

Reddit Inc

Novartis, Reddit and Check Point Software Technologies are included in this Analyst Blog.

The Zacks Analyst Blog Novartis, Reddit and Check Point Software Technologies

Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given at longer intervals but its current focus on other disease areas would provide for sales growth well into the 2030s.

Novartis: we are exploring obesity drugs but other areas provide growth for years

Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its prescription drugs.

Novartis lifts 2024 guidance for 3rd time on wider use of its drugs

Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc 1 , +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28% cc), Kisqali (+43% cc), Kesimpta (+28% cc), Pluvicto (+50% cc) and Leqvio (+119% cc) Core operating income margin 40.1%, +340 basis points (cc), mainly driven by higher net sales Q3 operating income grew +123% (cc, +106% USD); net income up +121% (cc, +111% USD) Q3 core EPS grew +20% (cc, +18% USD) to USD 2.06 Q3 free cash flow 1 of USD 6.0 billion (+18% USD) driven by higher net cash flows from operating activities Strong nine months performance with sales up +11% (cc, +9% USD) and core operating income up +20% (cc, +17% USD) Q3 selected innovation milestones: Kisqali FDA approval and positive CHMP opinion for HR+/HER2- stage II and III eBC Fabhalta FDA accelerated approval for IgAN Pluvicto FDA filing for pre-taxane mCRPC Full-year 2024 guidance raised 2 Net sales expected to grow low double-digit (from high single to low double-digit) Core operating income expected to grow high teens (from mid to high teens) Basel, October 29, 2024 – commenting on Q3 2024 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered another quarter of strong operational performance in Q3, with sales up 10% and core operating income up 20%.

Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance

We have narrowed our search to three large-cap stocks set to report earnings results tomorrow. These are: NVS, RDDT, CHKP.

Buy 3 Stocks Likely to Gain on Potential Q3 Earnings Beat

Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with potential $2.1 billion in milestone payments. Initial data from the phase 1 SAD/MAD study of MRT-6160 in healthy volunteers is expected in Q1 2025, potentially leading to mid-stage studies for UC and RA. MRT-2359 for MYC-driven solid tumors is also progressing, with phase 2 dose recommendations and updated results anticipated in the second half of 2024.

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash

Novartis AG (NYSE:NVS ) Renal Portfolio Update Conference Call October 28, 2024 8:00 AM ET Company Participants Sloan Simpson - Head, Investor Relations Shreeram Aradhye - President, Global Drug Development and CMO Victor Bulto - President, U.S. Business Dave Soergel - Executive Vice President, Global Head, Cardio, Renal, Metabolic Development Conference Call Participants Peter Welford - Jefferies Richard Vosser - JPMorgan Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Kerry Holford - Berenberg Christopher Uhde - SEB Seamus Fernandez - Guggenheim Securities Stephen Scala - TD Cowen Operator Good morning and good afternoon. And welcome to the Novartis Renal Portfolio Conference Call and Live Webcast.

Novartis AG (NVS) Renal Portfolio Update Call Transcript

Swiss pharmaceutical giant Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the U.S.-based biotech firm said on Monday.

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs

Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 glomerulopathy (C3G) treated with oral Fabhalta® (iptacopan) in addition to supportive care experienced clinically meaningful, sustained results at one year.1

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

Eli Lilly

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?

NVS vs. LLY: Which Stock Is the Better Value Option?

Novartis will report Q3 results next week and I expect the company to beat EPS and revenue estimates, and increase the full-year revenue and core operating income guidance. Key growth products should drive high single-digit revenue growth in the third quarter. Recent litigation updates on Entresto were negative and Novartis continues to anticipate a 2H 2025 generic launch.

What To Expect When Novartis Reports Q3 2024 Results

Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

News for Novartis Stock (NVS)